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Summary
Background Biomarkers of atopic dermatitis (AD) are largely lacking, especially in
infant AD. Those that have been examined to date have focused mostly on serum
cytokines, with few on noninvasive biomarkers in the skin.
Objectives We aimed to explore biomarkers obtainable from noninvasive sampling
of infant skin. We compared these with plasma biomarkers and structural and
functional measures of the skin barrier.
Methods We recruited 100 infants at first presentation with AD, who were treat-
ment naive to topical or systemic anti-inflammatory therapies, and 20 healthy
children. We sampled clinically unaffected skin by tape stripping the stratum cor-
neum (SC). Multiple cytokines and chemokines and natural moisturizing factor
were measured in the SC and plasma. We recorded disease severity and skin bar-
rier function.
Results Nineteen SC and 12 plasma biomarkers showed significant differences
between healthy and AD skin. Some biomarkers were common to both the SC
and plasma, and others were compartment specific. Identified biomarkers of AD
severity included T helper 2-skewed markers [interleukin (IL)-13, CCL17, CCL22,
IL-5]; markers of innate activation (IL-18, IL-1a, IL1b, CXCL8) and angiogenesis
(Flt-1, vascular endothelial growth factor); and others (soluble intercellular adhe-
sion molecule-1, soluble vascular cell adhesion molecule-1, IL-16, IL-17A).
Conclusions We identified clinically relevant biomarkers of AD, including novel
markers, easily sampled and typed in infants. These markers may provide objec-
tive assessment of disease severity and suggest new therapeutic targets, or
response measurement targets for AD. Future studies will be required to deter-
mine whether these biomarkers, seen in very early AD, can predict disease out-
comes or comorbidities.
What’s already known about this topic?
• Atopic dermatitis is a clinically heterogeneous condition with multiple clinical
manifestations and a complex pathogenesis.
• Systemic biomarkers of severity have been identified in adults, but are less well
defined in children.
• Biomarkers from the skin compartment have been based on biopsies to date.
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What does this study add?
• Noninvasive sampling can detect clinically relevant biomarkers in AD skin.
• These biomarkers may be useful for disease stratification, and provide insights into
the pathogenesis of infant AD.
• Innate immune activation is important in the epidermis in infantile AD.
What is the translational message?
• Noninvasive biomarkers can yield significant insights into infantile AD.
• They identify innate activation, the T helper 2 pathway and angiogenesis as impor-
tant pathways in this condition.
Atopic dermatitis (AD) is the most common inflammatory
skin disease, and the most common inflammatory disease of
childhood.1,2 It affects up to 20% of children, and up to 10%
of adults have a lifetime incidence of AD.3 The disease typi-
cally starts in infancy; in total 45% of all cases of AD begin
within the first 6 months of life, 60% begin during the first
year and 85% begin before 5 years of age.3 The importance
of both a skin barrier defect and immune dysregulation in AD
has been clearly demonstrated.4 Alterations and deficiencies in
stratum corneum (SC) proteins, particularly filaggrin, and
lipids have been implicated in the skin barrier deficiency.4,5
Several other pathogenic factors such as dysbiosis and epige-
netic modulation of the disease have been identified, adding
further layers of complexity.6 AD has a wide spectrum of clin-
ical presentations, natural history, severity, therapeutic
response and associated diseases.6 This diversity of clinical
phenotype likely reflects the complexity of the disease path-
omechanisms.
There is generalized skin dysfunction in AD, with abnor-
malities in both affected and unaffected skin. Clinically unaf-
fected skin has subclinical inflammation with skin barrier
dysfunction, a proinflammatory cytokine milieu and lympho-
cytic infiltration.7 A chronic mild inflammation has been
demonstrated in AD skin even in between flares.8 The role of
type 2 immune activation in AD pathogenesis is well estab-
lished; the T helper cell (Th)2 axis seems to be pathogenic
across all subtypes of AD.9,10 However, increasing complexity
in the immunopathogenesis of AD has become apparent, with
activation of the Th22, Th17/interleukin (IL)-23 and Th1
cytokine pathways reported.11 Acute AD lesions have elevated
Th2 and Th22 responses.12,13 In chronic AD lesions Th2 and
Th22 responses are increased along with Th1 axis activa-
tion.14,15 Th17 levels have been shown to be upregulated in
patients with both acute and chronic AD.14,16 IL-22 and IL-31
have also been identified as cytokines of interest, playing a
role in epidermal hyperplasia and itch, respectively.17–19
Despite AD being predominantly a disease of infancy and
childhood, there are few studies investigating the paediatric
immune profile. Paediatric and adult AD have clinical
differences, including the distribution of lesions20 and micro-
biome abnormalities,21 differences that may point to pathome-
chanistic diversity. Paediatric studies have demonstrated a
correlation between serum biomarkers and disease activity.
Biomarkers include IL-31, CCL17, CCL22, CCL27, eosinophils
and IgE.22–25 mRNA expression on DNA extracted from skin
biopsies has been studied in paediatric AD.26
Th2 expansion has been shown in peripheral blood in pae-
diatric AD, without other polar T-cell subsets in the blood; in
contrast, adult profiles showed Th2 and Th22 polarization.27
In infant skin there was a Th2 response but also innate and
IL-17-related inflammation.28 Nonlesional, clinically unaf-
fected skin in both adults and children has increased expres-
sion levels of cytokines with as high, or even higher levels in
children compared with adults.28,29
There is an ongoing need for therapeutic stratification of
new and established treatments. Biomarker profiles will be
central to this aim.6 As an example of this work, Thijs et al.
reported biological heterogenicity in AD when they investi-
gated biomarkers in adult patients, and demonstrated four
unique clusters of biomarkers.30 Infantile AD is an important
phenotype to characterize as it marks the commencement of
the disease. Here we profiled both the plasma and SC in
infants with AD. We analysed these biomarkers alongside
eczema severity assessments and transepidermal water loss
(TEWL). We identified clinically relevant biomarkers of AD
severity, including novel markers, easily sampled and typed in
infants.
Patients and methods
Study population
One hundred infants with AD were recruited, from November
2012 to November 2014, in a dedicated AD clinic in Our Lady’s
Children’s Hospital, Dublin. A single, experienced paediatric
dermatologist (M.A.McA.) assessed, recruited and treated all
patients. Patients had to be < 12 months of age with moderate
or severe AD, as determined by a Scoring Atopic Dermatitis
© 2018 The Authors. British Journal of Dermatology
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(SCORAD) score of ≥ 25, for ≥ 6 weeks’ duration. Further-
more, the patients had to be treatment naive, apart from the use
of emollients and hydrocortisone 1% cream or ointment.
Twenty control patients were recruited when attending Our
Lady’s Children’s Hospital, Dublin, for elective procedures
under general anaesthetic. Patients were recruited if they did
not have AD, any history suggestive of AD or any other
inflammatory skin disease. All infants and children were exam-
ined to ensure an absence of inflammatory skin disease. All
patients were asked to refrain from application of any topical
agents for 24 h prior to assessment. The study was conducted
in accordance with the Declaration of Helsinki and was
approved by the research ethics committee of Our Lady’s Chil-
dren’s Hospital, Dublin. Written informed consent was
obtained from all patients’ parents.
Clinical assessment
The patients met the Hanifin and Rajka criteria for the diagnosis
of AD.31 The age of onset of AD was recorded. Severity was
assessed using the SCORAD scale.32 All patients had moderate or
severe AD defined by SCORAD ≥ 25. Objective SCORAD
(oSCORAD) is derived from the SCORAD by not including sub-
jective scores of parental assessment of sleep loss and itch.
Stratum corneum transepidermal water loss
measurement
TEWL measurements were done under standardized conditions
(room temperature of 22–25 °C and humidity levels of 30–
35%). Patients were acclimatized for a minimum of 10 min,
with their volar forearm skin exposed. Measurements were
taken from an area of clinically unaffected skin on the volar
forearm using the Tewameter 300 (Courage + Khazaka elec-
tronic GmbH, Cologne, Germany).
Sampling of the stratum corneum by tape stripping
The SC was sampled using the previously described method,33
using circular adhesive tape strips (38 cm2, D-Squame; Mona-
derm, Monaco) and a D-Squame pressure instrument D500
(CuDerm, Dallas, TX, U.S.A.). Eight consecutive tape strips
were sampled, all from the same site, in nonlesional skin,
2 cm away from viable eczematous areas, and immediately
stored at 80 °C.
Blood sampling
Plasma was separated by centrifugation, pipetted into cry-
otubes and stored frozen at 80 °C until analysis.
Determination of filaggrin breakdown products in the
stratum corneum
Natural moisturizing factor (NMF) component analysis (his-
tidine, pyrrolidone carboxylic acid, trans- and cis-urocanic acid)
and proteins was performed on the fourth consecutive strip
according to the method previously described.33
FLG genotyping
All patients were screened for the nine most common filaggrin
mutations found in the Irish population (R501X, Y2092X,
2282del4, R2447X, S3247X, R3419X, 3702X, S1040X and
G1139X), as previously described.34
Cytokine analysis in tape strips and plasma samples
Cytokine concentrations in the SC and plasma were measured
using MESO QuickPlex SQ 120 (MSD, Rockville, MA, U.S.A.)
according to the manufacturer’s instructions, apart from the
samples being undiluted, and in the case of SC the sample
incubation time was extended to 16 h.
Cytokines were measured on preconfigured multiplex pan-
els, as follows. Proinflammatory panel: IL-1b, IL-2 and IL-13
in the SC and additionally interferon-c, IL-4, IL-6, IL-10, IL-
12p70 and tumour necrosis factor (TNF)-a in plasma. Chemo-
kine panel: CCL2, CCL3, CCL4, CCL13, CCL17, CCL22, CXCL8
and CXCL10 in the SC, and CCL5 and CCL11 in plasma. Cyto-
kine panel: granulocyte–macrophage colony-stimulating factor
(GM-CSF), IL-1a, IL-5, IL-7, IL-12p40, IL-15, IL-16 and IL-
17A in the SC, and TNF-b, IL-17A and vascular endothelial
growth factor (VEGF) in plasma. Vascular panel: C-reactive
protein, serum amyloid A (SAA), soluble intercellular adhesion
molecule (sICAM)-1 and soluble vascular cell adhesion mole-
cule (sVCAM)-1 in both SC and plasma. Angiogenesis panel:
Flt-1, Tie-2, VEGF-A and VEGF-C in the SC, and basic fibrob-
last growth factor, placental growth factor and VEGF-D in
plasma, as well as some singleplex assays (IL-18).
For statistical analysis, cytokine concentrations below the
detection limit (but above the bottom of the curve) or above
the detection limit were taken unchanged, and cytokine con-
centrations that were below the fit curve range (signal below
the bottom of the bottom-of-the-curve fit, no concentration
given) were assigned half the value of the lowest sample con-
centration below the detection limit to maintain the ranking
order. The limits of detection are given in Table S1 (see Sup-
porting Information).
Extraction of cytokines from the stratum corneum
The fifth consecutive tape strip was used to measure cytokine
levels in the SC. To determine the amount of soluble protein
and cytokines, 06 mL of phosphate-buffered saline (Merck,
Darmstadt, Germany) with 0005% Tween-20 (Sigma-Aldrich,
Zwijndrecht, the Netherlands) was added to each vial, and the
vials were left on ice for 30 min. Extraction was performed
with an ultrasound sonifier equipped with a probe (Salm &
Kipp, Breukelen, the Netherlands) for 15 min in ice water.
The extract was centrifuged (2 min at 15 000 g), and super-
natant aliquots of 60 lL were frozen at 80 °C until further
analysis. The amount of cytokine in the SC was normalized by
© 2018 The Authors. British Journal of Dermatology
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the protein content, which was determined using the Pierce
Micro BCA Protein Assay Kit (Thermo Fischer Scientific, Rock-
ford, IL, U.S.A.), with the bovine serum albumin supplied as
standard.
Statistical analysis
All calculations were performed using Prism 7 software
(GraphPad, La Jolla, CA, U.S.A.) and R 3.4.0 (R Foundation
for Statistical Computing, Vienna, Austria). The distribution of
data was tested by the Shapiro–Wilk normality test; P-values
were corrected for multiple testing using a Benjamini–Hoch-
berg procedure.35 The applied statistical test is indicated
within the figure or the figure legends.
Results
Study patients
We recruited 100 infants with moderate or severe AD and 20
healthy control infants. From this cohort, we analysed plasma
of 47 patient samples and 20 control samples. SC samples
were analysed for NMF in 74 patient samples and 18 controls,
and for cytokines in 66 patient samples and 13 controls.
Demographic details of the patients and controls analysed in
this study are outlined in Table 1. All raw study data are listed
in Tables S2 and S3 (see Supporting Information).
Measures of barrier function: unaffected atopic
dermatitis skin vs. healthy control skin
Patients with AD had significantly lower NMF levels and
higher TEWL readings than healthy controls (Fig. S1; see Sup-
porting Information). TEWL values in patients with AD and
healthy controls decreased exponentially with NMF (Fig. 1).
TEWL was associated with AD severity scores (Fig. S2; see
Supporting Information).
Stratum corneum and systemic biomarkers: atopic
dermatitis vs. healthy controls
Nineteen of 27 and 12 of 39 measured biomarkers, in SC and
plasma, respectively, showed significantly different levels in
infants with AD compared with healthy controls (Fig. 2).
While some biomarkers showed directional change (i.e. paral-
lel increase or decrease in patients with AD vs. healthy con-
trols), some of them showed discordance between SC and
plasma, or were significantly different only in SC or plasma.
For example, CCL17 and CCL22 were elevated in AD in both
SC and plasma. However, several inflammatory biomarkers
were significantly different from healthy controls only in the
SC; these included IL-1a, IL-1b, IL-15, IL-16, IL-18, IL-
12p40, SAA; chemokines CXCL8, CCL2 and CCL4; cell adhe-
sion biomarkers sVCAM-1 and sICAM-1 and vascular factors
VEGF-A and Flt-1. In contrast, VEGF-C, Tie-2 and CCL13 were
significantly elevated in plasma and undetectable or unchanged
in the SC (Fig. 2).
The biomarker profiles in plasma and SC not only differed
qualitatively but also showed distinct magnitudes of differ-
ence. Figure 3 demonstrates the fold changes in SC and
plasma biomarkers in infants with AD compared with healthy
controls. In the skin compartment the most significantly ele-
vated biomarkers in patients with AD were IL-18, CXCL8, Flt-
1, CCL22, CCL17 and sICAM-1. The most significant decreases
were observed in IL-15, GM-CSF, CCL4, IL-12p40, IL-1a, IL-
13 and IL-5. In plasma, the biomarkers CCL17, IL-5, VEGF-C,
GM-CSF and CCL26 had the most significant fold increases in
plasma of patients with AD compared with healthy controls,
while IL-4 and CXCL10 had the most significant decreases.
There was no significant differences in SC or plasma biomark-
ers following stratification for FLG mutations (Fig. S3; see Sup-
porting Information) or by the clinical presence or absence of
bacterial superinfection of AD (data not shown).
Stratum corneum and systemic biomarkers: correlation
with skin barrier function and disease severity
Correlation analysis between biomarkers and the biophysical
measures of barrier function (TEWL) and AD severity
(SCORAD and oSCORAD) are shown in Figure 4. Consistently
with the differences found between healthy controls and
patients with AD (Figs 2, 3), SC inflammatory biomarkers IL-
18, CXCL8, VEGF-A and Flt-1 showed the strongest associa-
tions with barrier function and AD severity, followed by
Table 1 Demographic and laboratory details of the study participants
Patients with AD Controls
Plasma SC Plasma SC
Total 47 66 20 13
Sex
Male 34 49 14 9
Female 13 17 6 4
Age (months)
Average 67 7 65 67
Range 0–11 0–11 0–12 0–12
Age at AD onset (weeks)
Average 118 11 – –
Range 2–44 2–44 – –
SCORAD
Average 48 452 – –
Range 25–913 25–85 – –
TEWL (g m2 h1)
Average 26 241 11 12
Range 85–539 83–539 4–156 81–156
FLG status
Wild-type 26 30 18 11
Heterozygous 18 27 2 2
Homozygous 3 5 0 0
Unknown 1 4 0 0
AD, atopic dermatitis; SC, stratum corneum; SCORAD, Scoring
Atopic Dermatitis; TEWL, transepidermal water loss.
© 2018 The Authors. British Journal of Dermatology
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CCL17, CCL22, sICAM-1 and sVCAM-1. In general, similar
strength of biomarker association was obtained with SCORAD
and oSCORAD. In plasma, biomarkers involved in the Th2
response, CCL22, CCL17 and CCL11, had the strongest associ-
ation with barrier function. Other plasma inflammatory
biomarkers associated with barrier function were CCL13, IL-
16 and IL-17A (Fig. 4). Among plasma biomarkers, CCL22
and TNF-a showed the strongest associations with disease
severity (oSCORAD). The skin barrier parameters TEWL and
NMF showed significant correlation with disease severity
(Fig. 4 and Fig. S2; see Supporting Information).
Discussion
This study is novel in several aspects. We studied a large sam-
ple size of treatment-naive infants at initial presentation of
moderate-to-severe AD. Our noninvasive technique has clear
advantages when studying skin disease in any group, but par-
ticularly in infants and children. A diverse range of signifi-
cantly associated and clinicopathologically relevant biomarkers
could be measured in the SC. The skin and systemic compart-
ments had distinct biomarker profiles; the skin compartment
in our study reflects cytokines dominant in the outer layers of
the SC, whereas the plasma profile reflects both tissue and sys-
temic responses. The SC sampling we employed is, compared
with full-thickness biopsy, selective for the epidermis and thus
more representative of mature cytokine protein expression in
this compartment than whole-biopsy mRNA. The techniques
we employed to measure biomarkers require further valida-
tion; however, in this exploratory study they have proved
promising. The identified biomarkers could broadly be
grouped into those critical in innate immune activation, Th2
immune activation and angiogenesis.
The role of innate immune activation in the pathogenesis of
infantile AD is supported by our findings of elevated IL-18
and IL-1b in the SC of patients with AD compared with
healthy controls. These findings are in keeping with recent
reports in early-onset AD, where changes in the innate
immune system were already detectable at birth.36 IL-18 levels
were particularly striking in our cohort: they were observed
in very high levels in the SC, were the most significantly
increased biomarker compared with healthy controls, were
strongly associated with barrier function, and also correlated
with disease severity. IL-18 is a member of the IL-1 family of
cytokines.37 Elevated expression of serum IL-18 is seen in chil-
dren and murine models.38,39 It has been shown to be ele-
vated in the SC of adults with AD40,41 and in the serum of
infants and children with AD, correlating with disease activ-
ity.42,43 We also found CXCL8 (IL-8) to be significantly
increased in the SC and correlated with disease severity and
barrier dysfunction, further supporting the role of innate acti-
vation. The pathomechanistic role of CXCL8 in AD has not
been studied. SC levels of CXCL8 have been shown to be clo-
sely correlated with SC IL-18; however, their relationship, if
any, in AD is unknown.44
Many cytokines and chemokines involved in the Th2
response were elevated in our cohort. CCL17 and CCL22 were
significantly elevated in both the skin and plasma, had notable
fold changes compared with controls, and were significantly
correlated with severity and barrier function. CCL17, produced
by Th2 cells and keratinocytes, is a key chemokine involved in
homing of CCR4-expressing T cells to the skin.45 CCL17 has
been detected in the inflamed skin of patients and in an ani-
mal model of AD.46,47 Serum CCL17 is strongly correlated
with disease severity in patients with AD, including infants,
and is the most reliable objective AD biomarker identified to
Fig 1. Relationship (exponential decay) between transepidermal water loss (TEWL) and natural moisturizing factor (NMF) in children with atopic
dermatitis (AD) and healthy controls.
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date.48–51 CCL22 is similar to CCL17 and is a chemoattractant
for CCR4-expressing skin-homing T cells.46
Meta-analysis of available studies reported a strong correla-
tion coefficient between CCL22 and disease severity in AD.51
IL-13 was elevated in the plasma of infants with AD. The role
of IL-13 has been extensively studied in AD, in both animal
models and humans, and its role in AD pathogenesis is well
established. The other prototypical type 2 cytokine is IL-4,
and its aberrant production has long been associated with ato-
pic disorders. We were unable to detect IL-4 in high enough
levels to measure it accurately. IL-13 levels have often been
shown to be elevated compared with IL-4 levels in inflamed
tissues.52 Murine work suggests that this is because primary
sources of IL-4 include basophils and conventional Th2 cells,53
in contrast to tissue Th2 cells and group 2 innate lymphoid
cells (ILC2s), which are the major producers of IL-13.54,55
The fact that ILC2s produce significant quantities of IL-13, but
not IL-4, may explain the quantities and timing of expression
of these cytokines.52
We demonstrated significantly decreased IL-5 levels in the
skin compartment of patients with AD compared with healthy
controls, in contrast to significantly increased levels in the
plasma that positively correlated with disease severity scores.
Th2 cells and mast cells are the major IL-5-producing
cells.56,57 ILC2s also produce Th2 cytokines, including IL-5.
ILC2s are involved in innate immune responses in allergy and
Fig 2. Levels of cytokines and chemokines in the stratum corneum of children with AD and healthy controls (CTRL). Stratum corneum: n = 66
(AD) and n = 13 (healthy); plasma: n = 47 (AD) and n = 20 (healthy). The values are log transformed, shown as boxplots with Tukey-style
whiskers. Differences in cytokine and chemokine levels between healthy children and children with AD were determined by two-tailed Welch’s t-
test or two-tailed Mann–Whitney test (raw data in Table S2; see Supporting Information). Benjamini–Hochberg corrected P-values:
****P < 00001, ***P < 0001, **P < 001, *P < 005. GM-CSF, granulocyte–macrophage colony-stimulating factor; IL, interleukin; PIGF,
placental growth factor; SAA, serum amyloid A; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule;
VEGF, vascular endothelial growth factor.
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Fig 3. Fold differences between cytokine and chemokine levels in the stratum corneum and in plasma of children with atopic dermatitis (AD),
and corresponding cytokine and chemokine levels in healthy children. The results are expressed as the mean  SEM. Stratum corneum: n = 66
(AD) and n = 13 (healthy); plasma: n = 47 (AD) and n = 20 (healthy). The fold difference was calculated by dividing the individual cytokine or
chemokine level in the SC and plasma of each child with AD by the corresponding mean cytokine or chemokine level in healthy children.
Differences in cytokine and chemokine levels between healthy children and children with AD were determined by two-tailed Welch’s t-test or
two-tailed Mann–Whitney test (raw data in Table S2; see Supporting Information). Benjamini–Hochberg corrected P-values: ****P < 00001,
***P < 0001, **P < 001, *P < 005. bFGF, basic fibroblast growth factor; CRP, C-reactive protein; GM-CSF, granulocyte–macrophage colony-
stimulating factor; IFN, interferon; IL, interleukin; PIGF, placental growth factor; SAA, serum amyloid A; sICAM, soluble intercellular adhesion
molecule; sVCAM, soluble vascular cell adhesion molecule; Th, T helper cell; TNF, tumour necrosis factor; VEGF, vascular endothelial growth
factor.
© 2018 The Authors. British Journal of Dermatology
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infection.58 Unlike in atopic lung disease, IL-5 has not been
studied extensively in AD. G€urkan et al. reported significantly
increased serum IL-5 levels in infants with AD compared with
controls, but did not demonstrate a correlation with disease
severity.59 Eosinophils constitutively express IL-31RA and
release proinflammatory cytokines and chemokines, including
IL-1b, IL-6, IL-31, CXCL1, CXCL8, CCL2, CCL18 and CCL26,
in response to IL-31.60 In keeping with elevated IL-5 levels
and eosinophil activation, we found elevated levels of CCL2,
IL-1b and CXCL8 in the SC.
Fig 4. Spearman correlation coefficients between stratum corneum (tape stripping, TS) and plasma biomarkers and atopic dermatitis severity
[Scoring Atopic Dermatitis (SCORAD) and objective SCORAD] and transepidermal water loss (TEWL). Benjamini–Hochberg corrected P-values:
****P < 00001, ***P < 0001, **P < 001, *P < 005. bFGF, basic fibroblast growth factor; CRP, C-reactive protein; GM-CSF, granulocyte–
macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; NMF, natural moisturizing factor; PIGF, placental growth factor; SAA,
serum amyloid A; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; Th, T helper cell; TNF, tumour
necrosis factor; VEGF, vascular endothelial growth factor.
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The third prominent biomarker profile in our cohort identi-
fies angiogenesis and lymphangiogenesis as key processes.
Biomarkers for these were significantly elevated in patients
compared with controls and correlated with disease severity
and barrier function. Angiogenesis is a hallmark of chronic
inflammatory skin diseases and plays a role in AD, although
this has not been extensively studied.61 Plasma and skin con-
centrations of VEGF-A are increased in patients with AD com-
pared with controls.62,63 The function of lymphangiogenesis
in AD and whether it represents a feasible therapeutic target is
unclear.61 It is possible that the biological role of lymphangio-
genesis in AD may not be pathogenic, but instead a response
to inflammation, attempting to rectify the disease through
transportation of allergens and inflammatory cells away from
the inflamed skin.64,65
Other biomarkers of note in our cohort were GM-CSF and
sICAM-1. GM-CSF levels were diminished in the SC and
increased in the plasma of infants with AD in our cohort.
Plasma levels negatively correlated with barrier function. GM-
CSF is synthesized and released by multiple cutaneous cells
including keratinocytes.66
Esaki et al. investigated early-onset paediatric AD biomark-
ers, using immunohistochemistry and real-time polymerase
chain reaction to study skin biopsies from 19 children.28
The children were within 6 months of disease onset, with a
mean age of 13 years. The authors reported Th17, Th9,
Th2 and Th22 activation in both lesional and nonlesional
skin and demonstrated significantly higher induction of
Th17-related cytokines (IL-17A, IL-19, CCL20, LL-37 and
peptidase inhibitor 3) in children with AD compared with
adults with AD and control patients.28 We did not demon-
strate any statistically significant difference in IL-17A levels
in the SC or plasma of patients with AD compared with
healthy controls. However, we did find an association
between IL-17A levels and barrier function, in keeping with
a recent murine study.67 It is notable that in the study of
Esaki et al. the statistically significant difference in IL-17A
levels in paediatric skin was observed when lesional skin
was compared with control children or skin of adults with
AD. There was no significant difference observed between
IL-17A levels in control children and nonlesional skin in
children with AD,28 and hence our IL-17A findings concur
with their results.
AD is a ‘multiaxis’ immune disease. It is becoming apparent
that different subtypes of the disease are associated with varia-
tions in immune profiles. Single-cytokine targeting may not
be fully effective in this complex disorder, and multicytokine
therapies or combination treatment may prove more effective.
Therapeutic options in AD are poised to increase rapidly,
along with drug costs. An objective and evidence-based
approach with respect to disease severity and therapeutic
response will become even more relevant. Combinations of
biomarkers with good predictive ability identified by multidi-
mensional data and multivariate analysis may be useful tools
in drug selection and justification in our patients with severe
AD.
We have demonstrated an SC and plasma biomarker profile
for infants with moderate-to-severe AD, a novel study in this
age group. Innate immunity, Th2 responses and lymphangio-
genesis appear to be important mechanisms in early disease.
Further understanding of the predictive abilities of biomarker
combinations may have clinical utility in objective severity
measurements, disease prognostication and measuring thera-
peutic responses.
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